BeOne Medicines received approval for its drug TEVIMBRA based on RATIONALE-315 trial results.
4 reports, 2 independent
Updated Aug 27
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BeOne Medicines received approval for its drug TEVIMBRA based on RATIONALE-315 trial results.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
BeOne Medicines (Switzerland)
company in Basel, Switzerland
Nothing else this week.
Coverage
Newest first; wire copies grouped- Business WireEuropean Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025 Final analysis of RATIONALE-315 demonstrates clear overall surviva
- Business WireBeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom’s Macroglobulinemia Decision highlights the promise of BGB-16673, an investigational and pot
- Insider MonkeyBeOne Medicines Ltd. (ONC) Wins EU Nod for Tevimbra We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. BeOne Medicines Ltd. stands ninth on our list. B
- Unknown outlet